Avantor (NYSE:AVTR) Given New $26.00 Price Target at Stifel Nicolaus

Avantor (NYSE:AVTR) had its price target dropped by equities research analysts at Stifel Nicolaus from $28.00 to $26.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 35.77% from the stock’s current price.

AVTR has been the subject of a number of other research reports. Raymond James cut their price objective on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a report on Tuesday, January 21st. Barclays cut their price target on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Monday. Wells Fargo & Company lowered their price target on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Robert W. Baird dropped their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Finally, UBS Group reaffirmed a “neutral” rating and set a $25.00 target price (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, Avantor presently has an average rating of “Moderate Buy” and a consensus price target of $27.08.

Avantor Stock Down 11.8 %

Shares of AVTR opened at $19.15 on Monday. The company has a market capitalization of $13.03 billion, a price-to-earnings ratio of 41.63, a PEG ratio of 3.87 and a beta of 1.28. Avantor has a 52 week low of $19.08 and a 52 week high of $28.00. The stock’s 50-day moving average price is $21.73 and its 200-day moving average price is $23.46. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same period last year, the firm posted $0.22 EPS. On average, sell-side analysts predict that Avantor will post 0.98 EPS for the current year.

Hedge Funds Weigh In On Avantor

Several hedge funds and other institutional investors have recently modified their holdings of AVTR. GAMMA Investing LLC raised its holdings in Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after acquiring an additional 1,285 shares during the last quarter. UMB Bank n.a. purchased a new stake in shares of Avantor in the third quarter valued at approximately $49,000. Livforsakringsbolaget Skandia Omsesidigt increased its holdings in shares of Avantor by 278.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after purchasing an additional 3,700 shares during the last quarter. Oliver Luxxe Assets LLC lifted its position in Avantor by 36.7% during the third quarter. Oliver Luxxe Assets LLC now owns 84,009 shares of the company’s stock worth $2,173,000 after buying an additional 22,534 shares in the last quarter. Finally, ORG Wealth Partners LLC purchased a new stake in Avantor in the 3rd quarter valued at $139,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.